Executive Leader in Life Sciences | Driving Strategy, Growing Profitability and Excelling Teams
I’m energized by the compelling data emerging around BioNTech SE BNT113 in head and neck cancer treatment. Coupled with recent investor conversations, it’s clear there’s real momentum behind the shift toward in vivo immunotherapy. By programming the immune system directly within the body, this approach promises to streamline production and logistics—potentially delivering transformative care at a dramatically lower cost than traditional cell and gene therapies. To put things in perspective: developing a typical cell or gene therapy today can cost upwards of US $1.9 billion from R&D through clinical trials. And that’s just R&D, Cost of goods/manufacturing alone for a gene therapy can be between $500,000 and $1 million. In contrast, true in vivo approaches (which bypass ex-vivo cell manipulation and personalized manufacturing) could dramatically reduce costs and broaden accessibility. BNT113 exemplifies this potential—a solution that could be cheaper, scalable, and faster to deploy. I’m excited to see how this innovation reshapes the therapeutic landscape—and thrilled to be part of this conversation in making immunotherapy more efficient and accessible. References: https://lnkd.in/exCJK4t8 https://www.genengnews.com
Well said.
It's inspiring to see such promising advancements in in vivo immunotherapy. How do you see regulatory hurdles evolving for these streamlined treatments? I enjoy your feed, let’s connect.
How do you see these lower costs impacting the list price in the end?
Absolutely fascinating insights! The potential of in vivo immunotherapy is indeed a revolutionary, especially when considering the logistical and economic benefits. It's exciting to think about how this could democratize access to cutting-edge treatments globally. Thanks for sharing such a thought-provoking perspective!
In vivo immunotherapy could do for cell and gene therapy what mRNA did for vaccines. Lower costs, faster timelines, and scalable access without sacrificing precision.
Director, Head of Immunology | Drug Discovery & Design Consultant | Immunology | CGT | Cross-Functional Collaboration | Conflict Resolution | Research and Development | Product & Business Development | Kayaker
2moLNP-mRNA is a great format for cancer vaccines and the early data are good... Still thoughtful that there doesn't seem to be good design around antigen processing and presentation pathways or a CD8+ T cell enhancing encoded adjuvant. The maximum cargo length of the mRNA is more than sufficient to cover these, and equivalent engineering (for an opposite system, suppressing autoimmunity to a specific antigen) easily doubled efficacy in our hands.